324 related articles for article (PubMed ID: 26045549)
61. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
[TBL] [Abstract][Full Text] [Related]
62. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
Olgan S; Humaidan P
Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
[TBL] [Abstract][Full Text] [Related]
63. Comparison of the standard GnRH antagonist protocol and the luteal phase estradiol/GnRH antagonist priming protocol in poor ovarian responders.
Mutlu MF; Mutlu İ; Erdem M; Güler İ; Erdem A
Turk J Med Sci; 2017 Apr; 47(2):470-475. PubMed ID: 28425233
[TBL] [Abstract][Full Text] [Related]
64. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
[TBL] [Abstract][Full Text] [Related]
65. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
[TBL] [Abstract][Full Text] [Related]
66. In vitro fertilization stimulation protocol for normal responder patients.
Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
[TBL] [Abstract][Full Text] [Related]
67. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
68. Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders--an observational pilot study.
Mitri F; Behan LA; Murphy CA; Hershko-Klement A; Casper RF; Bentov Y
Fertil Steril; 2016 Jan; 105(1):100-5.e1-6. PubMed ID: 26496380
[TBL] [Abstract][Full Text] [Related]
69. Effect of the initiation of progesterone supplementation in in vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial.
Gao J; Gu F; Miao BY; Chen MH; Zhou CQ; Xu YW
Fertil Steril; 2018 Jan; 109(1):97-103. PubMed ID: 29175065
[TBL] [Abstract][Full Text] [Related]
70. Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction-intrauterine insemination to in vitro fertilization conversions, independent of age and estradiol level on the day of human chorionic gonadotropin administration.
Quaas AM; Missmer SA; Ginsburg ES
Fertil Steril; 2010 Feb; 93(2):605-8. PubMed ID: 19324340
[TBL] [Abstract][Full Text] [Related]
71. Follicular synchronization using transdermal estradiol patch and GnRH antagonists in the luteal phase; does it increase oocyte yield in poor responders to gonadotropin stimulation for in vitro fertilization (IVF)? A comparative study with microdose flare-up protocol.
Ata B; Zeng X; Son WY; Holzer H; Tan SL
Gynecol Endocrinol; 2011 Nov; 27(11):876-9. PubMed ID: 21495800
[TBL] [Abstract][Full Text] [Related]
72. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
73. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
74. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
[TBL] [Abstract][Full Text] [Related]
75. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
76. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
Berin I; Stein DE; Keltz MD
Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
[TBL] [Abstract][Full Text] [Related]
77. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
78. Elevated early follicular progesterone levels and in vitro fertilization outcomes: a prospective intervention study and meta-analysis.
Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
Fertil Steril; 2014 Aug; 102(2):448-454.e1. PubMed ID: 24929258
[TBL] [Abstract][Full Text] [Related]
79. Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature.
Merviel P; Menard M; Cabry R; Scheffler F; Lourdel E; Le Martelot MT; Roche S; Chabaud JJ; Copin H; Drapier H; Benkhalifa M; Beauvillard D
Reprod Sci; 2021 Feb; 28(2):495-509. PubMed ID: 32886340
[TBL] [Abstract][Full Text] [Related]
80. GnRHa flare and IVF pregnancy rates.
Confino E; Zhang X; Kazer RR
Int J Gynaecol Obstet; 2004 Apr; 85(1):36-9. PubMed ID: 15050465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
